{"ticker": {"uuid": "30b13b0c-b5db-41ae-aff1-431d72dbed7e", "symbol": "CERT", "name": "Certara Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Health Information Services"}, "articles": [{"title": "Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026", "summary": "Certara, Inc. (Nasdaq: CERT) announced that it will release its second quarter 2026 financial results before market open on Tuesday, August 4th, 2026. Company management will host a conference call at 8:30 AM ET to discuss the results, and a live webcast will be available on the ", "url": "https://www.manilatimes.net/2026/07/16/tmt-newswire/globenewswire/certara-to-report-second-quarter-2026-financial-results-on-august-4th-2026/2385457/amp", "source_name": "The Manila Times", "published_at": "2026-07-16T04:27:00", "published_display": "16 Jul 2026 04:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara to report Q2 2026 financial results on August 4", "summary": "Certara, Inc. announced it will release its second-quarter 2026 financial results before market open on August 4, 2026, followed by a conference call at 8:30 AM ET. The company, a specialist in model-informed drug development, requires investors to register online in advance to p", "url": "https://scanx.trade/stock-market-news/companies/certara-to-report-q2-2026-financial-results-on-august-4/45698143", "source_name": "scanx.trade", "published_at": "2026-07-15T22:10:22", "published_display": "15 Jul 2026 22:10", "sentiment": "negative", "sentiment_pct": 20, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara sets Aug. 4 call to discuss second-quarter results", "summary": "Certara (Nasdaq: CERT) announced it will release its second-quarter 2026 financial results before market open on Tuesday, August 4, 2026. Company management will host a conference call to discuss the results at 8:30 AM ET, and investors are required to register online in advance.", "url": "https://www.stocktitan.net/news/CERT/certara-to-report-second-quarter-2026-financial-results-on-august-v9c3hr8cwqdg.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:10:22", "published_display": "15 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BlackRock, Inc.'s Strategic Acquisition of Certara Inc. Shares", "summary": "BlackRock, Inc. has increased its stake in Certara Inc. by acquiring an additional 3,724,184 shares, bringing their total holdings to 18,032,062 shares. This strategic move, despite Certara's current financial challenges and negative year-to-date performance, suggests BlackRock's", "url": "https://www.gurufocus.com/news/8958974/blackrock-incs-strategic-acquisition-of-certara-inc-shares", "source_name": "GuruFocus", "published_at": "2026-07-15T01:03:02", "published_display": "15 Jul 2026 01:03", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dimensional Fund Advisors details Certara Inc (CERT) 3.9% ownership position", "summary": "Dimensional Fund Advisors LP has filed an amended Schedule 13G, disclosing a beneficial ownership of 6,022,686 shares of Certara Inc (CERT) common stock, which represents 3.9% of the class as of June 30, 2026. Dimensional holds sole voting power over 5,913,513 shares and sole dis", "url": "https://www.stocktitan.net/sec-filings/CERT/schedule-13g-a-certara-inc-amended-passive-investment-disclosure-5fc0a866be4a.html", "source_name": "Stock Titan", "published_at": "2026-07-14T17:03:02", "published_display": "14 Jul 2026 17:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara (CERT) Taps NVIDIA For AI Drug Development, Is It A Bargain?", "summary": "Certara (CERT) announced a partnership with NVIDIA to integrate the BioNeMo Agent Toolkit into its open AI platform for drug development, driving recent investor interest and a 30-day share price increase of over 30%. While some valuation models suggest Certara is undervalued due", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-cert/certara/news/certara-cert-taps-nvidia-for-ai-drug-development-is-it-a-bar/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-14T10:42:15", "published_display": "14 Jul 2026 10:42", "sentiment": "positive", "sentiment_pct": 62, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Certara (CERT)'s NVIDIA BioNeMo Partnership Means For Shareholders", "summary": "Certara announced a partnership with NVIDIA to integrate the BioNeMo Agent Toolkit into its AI-driven biosimulation platform. This collaboration aims to enhance drug development tasks and reshape computational biology workflows, aligning with Certara's strategy to make AI-enabled", "url": "https://www.sahmcapital.com/news/content/what-certara-certs-nvidia-bionemo-partnership-means-for-shareholders-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-10T01:10:58", "published_display": "10 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara faces securities fraud probe after Q1 r...", "summary": "Certara, Inc. is under investigation by Pomerantz LLP for potential securities fraud. This probe follows a Q1 2026 report revealing a 4% decline in services revenue, a 14% drop in bookings, and the company's decision to exit its regulatory business segment due to inconsistent per", "url": "https://pluang.com/en/news-feed/peringatan-investor-pomerantz-selidiki-tuntutan-pemegang-saham-certara", "source_name": "Pluang", "published_at": "2026-07-09T21:45:06", "published_display": "09 Jul 2026 21:45", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT", "summary": "Pomerantz LLP is investigating potential claims on behalf of investors of Certara, Inc. (NASDAQ: CERT) regarding possible securities fraud or unlawful business practices. This investigation follows Certara's reported decline in services revenue and bookings in Q1 2026, its exit f", "url": "https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-certara-inc---cert-302822346.html", "source_name": "PR Newswire", "published_at": "2026-07-09T17:39:00", "published_display": "09 Jul 2026 17:39", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BlackRock (CERT) discloses 18.0M shares; 11.6% ownership reported", "summary": "BlackRock, Inc. has filed an amended Schedule 13G disclosing beneficial ownership of 18,032,062 shares of Certara, Inc. common stock, which represents an 11.6% stake in the company. The filing specifies that BlackRock holds sole voting power over 17,841,248 shares and sole dispos", "url": "https://www.stocktitan.net/sec-filings/CERT/schedule-13g-a-certara-inc-amended-passive-investment-disclosure-1c05b13791df.html", "source_name": "Stock Titan", "published_at": "2026-07-09T01:10:56", "published_display": "09 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AI Chips Today - Certara-NVIDIA Partnership Revolutionizes AI in Drug Development", "summary": "Certara has partnered with NVIDIA to integrate the NVIDIA BioNeMo Agent Toolkit into its AI platform for drug discovery and development. This collaboration aims to accelerate drug development by using AI-driven agents and biosimulation models to computationally simulate human bio", "url": "https://simplywall.st/stocks/us/semiconductors/nasdaq-nvda/nvidia/news/ai-chips-today-certara-nvidia-partnership-revolutionizes-ai", "source_name": "Simply Wall Street", "published_at": "2026-07-08T11:10:17", "published_display": "08 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara partners with Nvidia to integrate AI agents into drug development platform", "summary": "Certara, Inc. announced a partnership with Nvidia to integrate AI-driven agent technology, specifically Nvidia\u2019s BioNeMo Agent Toolkit, into its drug development platform. This collaboration aims to enhance drug development processes by generating insights across various stages, ", "url": "https://www.investing.com/news/company-news/certara-partners-with-nvidia-to-integrate-ai-agents-into-drug-development-platform-93CH-4779100", "source_name": "Investing.com", "published_at": "2026-07-08T01:10:56", "published_display": "08 Jul 2026 01:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nvidia Powers AI Agent Strategies for Certara, Silo Pharma - NVIDIA (NASDAQ:NVDA)", "summary": "Nvidia is expanding its influence in the life sciences AI sector through collaborations with Certara Inc. and Silo Pharma Inc. Certara is integrating Nvidia's BioNeMo Agent Toolkit into its AI-driven drug development platform to enhance drug discovery workflows, while Silo Pharma", "url": "https://www.benzinga.com/news/health-care/26/07/60316675/certara-silo-pharma-advance-ai-agent-strategies-with-nvidia-initiatives", "source_name": "Benzinga", "published_at": "2026-07-07T18:41:02", "published_display": "07 Jul 2026 18:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara teams up with Nvidia to strengthen AI platform with BioNeMo toolkit (CERT)", "summary": "", "url": "https://finance.yahoo.com/m/1806ddc8-7492-3334-96ab-5de0bc407511/certara-teams-up-with-nvidia.html", "source_name": "InvestorsHub", "published_at": "2026-07-07T12:54:23+00:00", "published_display": "07 Jul 2026 12:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent Toolkit", "summary": "Certara is partnering with NVIDIA to enhance its integrated AI platform for drug discovery and development using the NVIDIA BioNeMo Agent Toolkit. This collaboration aims to unify Certara's biosimulation software, proprietary datasets, and scientific expertise with AI-driven agen", "url": "https://www.manilatimes.net/2026/07/07/tmt-newswire/globenewswire/certara-accelerates-drug-discovery-and-development-with-nvidia-bionemo-agent-toolkit/2379819", "source_name": "The Manila Times", "published_at": "2026-07-07T12:05:20", "published_display": "07 Jul 2026 12:05", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara teams with NVIDIA to speed drug discovery with AI agents", "summary": "Certara announced a partnership with NVIDIA to integrate the NVIDIA BioNeMo Agent Toolkit into its open integrated AI platform. This collaboration aims to accelerate drug discovery and development by enabling AI agents to autonomously generate specialized insights across the life", "url": "https://www.stocktitan.net/news/CERT/certara-accelerates-drug-discovery-and-development-with-nvidia-bio-xvymzo9l011a.html", "source_name": "Stock Titan", "published_at": "2026-07-07T12:00:20", "published_display": "07 Jul 2026 12:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Certara, Inc. \u2013 HAM:700", "summary": "This article provides the \"Price to earnings forward\" value for Certara, Inc. (HAM:700) on the Hamburg Stock Exchange. It includes details about the period, value, and change, noting that the data is provided by FactSet Research Systems Inc.", "url": "https://www.tradingview.com/symbols/HAM-700/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T16:39:18", "published_display": "06 Jul 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Certara, Inc. \u2013 HAM:700", "summary": "This article provides financial information for Certara, Inc. (HAM:700), specifically focusing on its Price to Sales forward metric. The content highlights the company's stock exchange listing on the Hamburg Stock Exchange and indicates that no recent trades have occurred.", "url": "https://www.tradingview.com/symbols/HAM-700/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T12:13:30", "published_display": "05 Jul 2026 12:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Certara, Inc. \u2013 NASDAQ:CERT", "summary": "This article provides financial information for Certara, Inc. (NASDAQ: CERT), focusing on its enterprise value to revenue forward. The content appears to be a stub or a section of a larger financial data report, likely from TradingView, given the source and formatting. It details", "url": "https://www.tradingview.com/symbols/NASDAQ-CERT/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T02:10:39", "published_display": "05 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Certara, Inc. \u2013 HAM:700", "summary": "This article provides a brief mention of Certara, Inc.'s enterprise value to revenue forward, listed on the Hamburg Stock Exchange under the ticker HAM:700. It appears to be a stub or a section within a larger financial data platform, indicating the company's financial overview i", "url": "https://www.tradingview.com/symbols/HAM-700/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T01:40:28", "published_display": "05 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara (CERT) Could Be 33% Below Fair Value Following Russell Index Shift", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Certara (CERT) Quietly Recasting Its Small-Cap Identity Around Biosimulation Advisory Leadership?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/certara-cert-quietly-recasting-small-170847792.html", "source_name": "Simply Wall St.", "published_at": "2026-07-02T17:08:47+00:00", "published_display": "02 Jul 2026 17:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Certara (CERT) Joining the Russell 2000 Recast Its Biosimulation Investment Narrative?", "summary": "Certara, Inc. (CERT) has been reclassified into the Russell 2000 index, indicating a shift towards smaller-cap status, while also launching its Bio Venture Catalyst for early-stage biotechs and announcing a CFO transition. This article examines how the index change, coupled with ", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-cert/certara/news/does-certara-cert-joining-the-russell-2000-recast-its-biosim", "source_name": "Simply Wall Street", "published_at": "2026-07-01T18:10:33", "published_display": "01 Jul 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should You Investigate Certara, Inc. (NASDAQ:CERT) At US$6.36?", "summary": "This article evaluates whether Certara, Inc. (NASDAQ:CERT) is a worthwhile investment at its current price of US$6.36. It likely delves into the company's financials, market position, and future prospects to help potential investors make an informed decision.", "url": "https://news.futunn.com/en/post/75335485/should-you-investigate-certara-inc-nasdaq-cert-at-us-6", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-06-30T23:39:58", "published_display": "30 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara, Inc.(NasdaqGS: CERT) added to Russell 2000 Index", "summary": "Certara, Inc. (NasdaqGS: CERT), a provider of biosimulation software and services, has been added to the Russell 2000 Index. This inclusion means the company's stock will now be part of this widely recognized small-cap index, potentially increasing its visibility and liquidity. T", "url": "https://www.marketscreener.com/news/certara-inc-nasdaqgs-cert-added-to-russell-2000-index-ce7f5fdfda8ff724", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T18:40:11", "published_display": "29 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Certara, Inc. \u2013 NASDAQ:CERT", "summary": "This article displays the \"Enterprise value to EBITDA forward\" for Certara, Inc. (NASDAQ: CERT) on TradingView. It provides financial data for the company within the Technology Services sector. The page highlights market information, with various disclaimers regarding data provid", "url": "https://www.tradingview.com/symbols/NASDAQ-CERT/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T00:11:22", "published_display": "29 Jun 2026 00:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara, Inc. (CERT) Investigation: Bronstein, Gewirtz & Grossman", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Certara, Inc. (NASDAQ:CERT) following a significant drop in its stock price. This comes after Certara reported a decline in services revenue and bookings for Q1 2026, alongside an exit from its regulatory busin", "url": "https://natlawreview.com/press-releases/certara-inc-cert-investigation-bronstein-gewirtz-grossman-llc-encourages-0", "source_name": "The National Law Review", "published_at": "2026-06-28T14:09:55", "published_display": "28 Jun 2026 14:09", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Certara, Inc. \u2013 NASDAQ:CERT", "summary": "This article provides financial data for Certara, Inc. (NASDAQ: CERT), specifically focusing on its enterprise value to EBIT forward metric. It also lists general information about the company on TradingView, including market data, news, and community features.", "url": "https://www.tradingview.com/symbols/NASDAQ-CERT/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T12:10:05", "published_display": "28 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Certara, Inc. \u2013 NASDAQ:CERT", "summary": "The article displays the \"Price to book forward\" metric for Certara, Inc. (NASDAQ: CERT). It appears to be a financial data point provided by TradingView, with data sourced from ICE Data Services and FactSet Research Systems Inc.", "url": "https://www.tradingview.com/symbols/NASDAQ-CERT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T06:41:43", "published_display": "28 Jun 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara, Inc. Actuals & Estimates (NASDAQ:CERT)", "summary": "This article provides an overview of Certara, Inc. (NASDAQ:CERT) stock, including current price, historical performance, analyst forecasts, and financial data. It details information such as market capitalization, earnings reports, revenue, net income, and volatility, while also ", "url": "https://www.tradingview.com/symbols/NASDAQ-CERT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T14:41:24", "published_display": "25 Jun 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CERT Stock Slides As Certara Faces Probes And CFO Exit", "summary": "", "url": "https://news.google.com/rss/articles/CBMidEFVX3lxTFAydkZRNkVqQktqZkRaR2tIYlJMbFpXSjF1UjJRamgteU5Ya0JYYV9ESlFqUldfbGgzZXltXzRBRlJDNEJuMkJYQktmZmtJSk84U3QtbU5UVXFhY29Ma21jWHNaU2N3dGZ6Nm9aNVlLX3QyeTU5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-06-21T07:00:00+00:00", "published_display": "21 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara (CERT) Stock Sees Fair Value Edges Lower As Analysts Trim Targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPYlVnYURjd3J5VEMxME1zRjdVZ1FwZlh4T0dDU0xKZ3B0UjNfYmVuSjBaUjFjZWRjZ2RKbFJGOFMxTElHWjFLWXpYa2t6dHFxVi1tc1hpSGM3M3lSSjZVTTVIT3A4eGZPc0NwSjNXYkF3QlU5Xzc0V2d4TGFmdVI1NzhSLTJ4ZzFLY290b01BSldqZHc2aWZVag?oc=5", "source_name": "Market source", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CFO transition at Certara (NASDAQ: CERT) as company reaffirms 2026 guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOTlBPeFkxR1hEakxZOVhJX2FTckxsblVlMnIwczZkalFxbEY4RzB3aFJTYUttRUduTnYydkgyWmxWMmczNi1iMlEtb3lmc2JIWlh0V29rOWVsczQwQS1vcXVSa0lMeGhXbThPYWt3akFyUlRFai1KNldRb2ZqX1JxZ3pWNUUyVFItNm5RN3YweUZ6SG9qQmxDVnlWYUwxY0FMbHc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Consider Buying Certara, Inc. (NASDAQ:CERT)?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Certara (CERT) Investors Can Read The Quiet Shift In The Valuation Story", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNdjkxNXgyQ2pueHZYOGwxYW1EaFNVbEF0U3Z5OHZfb2JpbldGbzdqN0JnS2hXMkQ2RkxPbk5Mb0FFYmJpTC0yUWxoOEpwbjhOVUFReEtEY21wbkVYSE56NmtneVZZaWNCb3ozVWZXaVVqWjlzb2RIc3B1YW1USXRoNkc3YmVtQzFXUV9XZXJMYlRObWM3NGQxbmZWenpNMkE?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Now An Opportune Moment To Examine Certara, Inc. (NASDAQ:CERT)?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOTk12cUdDNUFHT19jUGRweXN5a3pCU0VPODRoZHEyVERfU2VqX2c2RTY0blZMVGpEU2ZPdUtQQzBrTmlDb0lyQUVzYVBBUHpUb3lGSDBCTGQ0TjMyTEdMZkNiY3l0VS10czIwR3pfcVRnZnlMUU1nNzdzaUhRb3c3Ul9rcXFQenl6XzlNbFRRbjFfbjJaX2FnODNmTzZ6a0dINkVR?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara Q1 2026 Earnings: EPS Misses Estimates but Stock Gains 1.35% - Final Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOS25yWUlfN0llM1FDMTRDUl9uR2hKZDFFY2VXX0pfZVNRaXYwMTBuTExtSVl5TnhaTmpFWU9mRGxtUTBqeXRhNlRfa1haQlpJZGo3TXVOMmZWWnItX3RfV2lVQU04bDAybDU2REJKSzJLU29fTVpyTUhMTDMtcEs0T1JydVdTWjRhZkR6YXBKZ2hRVTRHalp1Wjdra2NyOERKaTVtcncyQWc5V0U?oc=5", "source_name": "lwvtexas.org", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 31, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intel, Micron gain premarket; Certara slips", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOS05EelRuNjRVaFpPTkpEcjJhbVMyQmlfWEd1dmx5N0FYQlN6azJuOGxDVng3ZlF5bEFSOHdRNWhFZVU0YUlleUNoQWVQQU1BNEFDS1UwT19FdzRBWlNIcWVNZkxydG5FcEx5V3VHeFJLSzN3ckpGci1MQUhqM0dpbExQYTdMUjRuaTBUcGtfN2lQSnFqREREdWZTOVk5bkE?oc=5", "source_name": "Investing.com", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara (NASDAQ:CERT) Q1 2026: Software Shines, but Divestiture and Mixed Metrics Weigh on Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxQNk1KWjA2RU9yN0hMZDdnampSTzNCRkIxTHZCX1ZZYjdCdDJ6VGg4T0s0TnNLWWFQaHdhVFljU1NRdTluay1VVDA1ZEg5YkdXQUw2Y1ZHM2wtX2laeElCejRBdURuSkJkQVNDRGc2NXN2aktiNXlOV0VfZC1zUEZYQkVMdzUzSlRVQU1ISTlJeVlVVEJRVU5HSkl2WkNUcEprZHNZQkVkRURMT2lMc3NDQXJZYUVSbkRuekh5M2FvOTZYWmZNT29xLVI1ZHN2RWJPNlNwTUVKbHJOLWtN?oc=5", "source_name": "ChartMill", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara (CERT) Shares Slide After Weak Full-Year Guidance Overshadows Revenue Beat", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOZ1R4Zm5PUHFodG9oaVpBXzlWcjRneGpNV0VtZHFpZDRPSnd4clY5YjBtNVB0VDVBSUVBQ1VHRnJkNmZNYXN2bnMxWGhOSzVGREVMQUlzNHBvSTR4YW1DUURNck5qTmFteVlmMWItRC10Szk3azhOb1FTX2g1bUZ0VFM5SV92QWFQTlZId2hyMmZsdXQ5MDA4OEctY0MtNTN4?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara, Inc. (CERT) Q1 Earnings Miss Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOeEx0dEpKMXVseXN3eXVZNXFpTDVoeDJRa3p4eW1HLWNaMHJGWkxJTHJOaGJ4eE43UWlHY0hhZk5vTmdPZzFmNFZ2TWdvaGZrcVRfVXNXNUk0aXh2TTNZem13eWZHS2FDdWp2RmVnVkNENDJoSXFCYjJmbG9OWHhsWEVEOFY2dFpiWE5wamIxbDAxVW80S2J4Nw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara Insider Ups Holding During Year", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQcnNWWUZQQVVYWU1oTG9ZRTFvSDN1STgyTHpuM2t0c3JiOEE3VXgxWjE0Q01NRWJMYVhkVjVYR08taC1UYWZNaGdSRmphYlJzeXdMeW14UWxkcUp2M3hwYk5zZkk1bUYxaVpBeHZEeE1aVkVmQ0I4aUk1T2JXMjlnalBIV3N2dUNBX1BQXzhwT05PLWVPZEhWekZldE5sYUl4YlI1TG5KVkRfNlHSAbABQVVfeXFMT0hpV25pR1NTZnRibEpOU3FWTzVpVEpUaVVmM3Nxb3UzOElDZExpZkxhbzVKdlhkLXU2eXVyVEhRcTdUSDdjcTZ2U3NreVI0SWNPU0dqQW9RREViR2NZZkg4X0hucHhnSENLUFotQ1B3RGlmcG1kaGxxZGN1SUt0T0g5ZGllbkFqQzB2YkFRcmZweXVUMG5ESTlYMTN0V1BGSWw0MmJrNWpNSVZKem8tVTk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Certara (CERT) Story Is Shifting As Analysts Recut Targets And Expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxObmdtWDBoYnhEaUlSN2JwSjZDRGlEbHhuelBaME5TZ0picHZIWnp6R21JMFRFTEtmX0FSNUtENUg4Y0poN2JuN2N0c0QxbkFJajVqNmNJN2hOdU1iZFVkdXdGRDFzSHdpc3g1alVsckE4a0VLdU0tMlEyVVA0U3NiR2tNcnZLMkxhbFc3a0s1OUNxRmc4UEd5UnNRZ253dnZCZ1Y4?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veristat to Acquire Certara's Regulatory and Medical Writing Business in Expansion of CRO Capabilities", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOc3lSU2JJY1E5M2NSZFJNcXNHWV9NWWVQZmxONTFocVg4b0ZyMlNWUVpIakJvQms2U1FVVWpNV3ZfUm1IcEFodkVnc2lXdmQtdEhaVXJUY2tKRWdCcU9FS052UmRXczI1dUlBNXN1QXluSm55a05vU1FCNVpyaGJRakQ4SnRHTmhEMXhVMkQyVDFHR3FYUUVHSTVxejNEWm91Y1hjUXJxYXc1MW05WlV6aFZCTDZqMW1xeHFCQVVEMlBkQzU2YWd3S3F1U25xT0M5WXc?oc=5", "source_name": "Applied Clinical Trials Online", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Certara (CERT) Story Is Evolving As Price Targets Reset And Growth Plans Lag", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQbHNPdGpBVnlDNVhWbVotbzRyT0Z4UkVNSHNqZE16dmpwd3BYdWpJa1lvdmxkbDlvaEtwU2h6aFNtZlhqQ09UQ2lXR094MDVkeVNtQld3dTdLUlJxVVREd01uQ3oyYUp3bldwOWdzcUwxeFNJWHZ6cHNhRnV2ZVJlcHBJLUUxWDF3dXJHRTEyZXZFWEEtZl91X1FKVHpSNWs?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara, Inc.'s (NASDAQ:CERT) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara, Inc. Appoints Jon Resnick as CEO, Succeeding William Feehery, Effective January 1, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNWl9ORjliejE3VUdsRnVjOEVxSkg1UFllZWtSTXcyQWF1eGRJVWhsdkZMal82eWx4aElrUUhFb0Vwc0thNnBwN0VtaV91U2pDWmdCTnpDdTBJUVpiRGxzUkJfTlphdHRJQ3lsbDBGN3FDbUxvWXVfaVRzb1VVSEYtWkR4N2VILTQ0MFhiRVJCWUFWR3pzXzRCdDJ6X1F5QUJjZ29XV05zZXB0MXM5MzIzYldib1l4amw3b2F1N1hWMF9iYlpqZExXRjhiRWRSa1h5MDRR?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-12-11T08:00:00+00:00", "published_display": "11 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CERT SEC Filings - Certara, Inc. 10-K, 10-Q, 8-K Forms", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE5BaHdBSlBLZXNNRjFZajdZY1JXZW5TWmh6N19LeVk4UFlNUjM4Q25MazM5bTJKNXJmQTk0NWtaQ0kzcUZsWERKczJPRjljVlV2NVVzbE4xSQ?oc=5", "source_name": "Stock Titan", "published_at": "2025-08-06T21:14:43+00:00", "published_display": "06 Aug 2025 21:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara (CERT) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5ReGdKWGNUc3h4LVJsZHhsZlJrN3lIRmxqOGVrUV9EZjVIWkUzc3VqbnIzTHBIcWNBbm93WXluRm0tcHp2TnpJWW5ueEViUzZrRVY4?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:56:10+00:00", "published_display": "25 Apr 2025 00:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026", "summary": "Certara, Inc. (Nasdaq: CERT) announced that it will release its second quarter 2026 financial results before market open on Tuesday, August 4th, 2026. Company management will host a conference call at 8:30 AM ET to discuss the results, and a live webcast will be available on the ", "url": "https://www.manilatimes.net/2026/07/16/tmt-newswire/globenewswire/certara-to-report-second-quarter-2026-financial-results-on-august-4th-2026/2385457/amp", "source_name": "The Manila Times", "published_at": "2026-07-16T04:27:00", "published_display": "16 Jul 2026 04:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara to report Q2 2026 financial results on August 4", "summary": "Certara, Inc. announced it will release its second-quarter 2026 financial results before market open on August 4, 2026, followed by a conference call at 8:30 AM ET. The company, a specialist in model-informed drug development, requires investors to register online in advance to p", "url": "https://scanx.trade/stock-market-news/companies/certara-to-report-q2-2026-financial-results-on-august-4/45698143", "source_name": "scanx.trade", "published_at": "2026-07-15T22:10:22", "published_display": "15 Jul 2026 22:10", "sentiment": "negative", "sentiment_pct": 20, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara sets Aug. 4 call to discuss second-quarter results", "summary": "Certara (Nasdaq: CERT) announced it will release its second-quarter 2026 financial results before market open on Tuesday, August 4, 2026. Company management will host a conference call to discuss the results at 8:30 AM ET, and investors are required to register online in advance.", "url": "https://www.stocktitan.net/news/CERT/certara-to-report-second-quarter-2026-financial-results-on-august-v9c3hr8cwqdg.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:10:22", "published_display": "15 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BlackRock, Inc.'s Strategic Acquisition of Certara Inc. Shares", "summary": "BlackRock, Inc. has increased its stake in Certara Inc. by acquiring an additional 3,724,184 shares, bringing their total holdings to 18,032,062 shares. This strategic move, despite Certara's current financial challenges and negative year-to-date performance, suggests BlackRock's", "url": "https://www.gurufocus.com/news/8958974/blackrock-incs-strategic-acquisition-of-certara-inc-shares", "source_name": "GuruFocus", "published_at": "2026-07-15T01:03:02", "published_display": "15 Jul 2026 01:03", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dimensional Fund Advisors details Certara Inc (CERT) 3.9% ownership position", "summary": "Dimensional Fund Advisors LP has filed an amended Schedule 13G, disclosing a beneficial ownership of 6,022,686 shares of Certara Inc (CERT) common stock, which represents 3.9% of the class as of June 30, 2026. Dimensional holds sole voting power over 5,913,513 shares and sole dis", "url": "https://www.stocktitan.net/sec-filings/CERT/schedule-13g-a-certara-inc-amended-passive-investment-disclosure-5fc0a866be4a.html", "source_name": "Stock Titan", "published_at": "2026-07-14T17:03:02", "published_display": "14 Jul 2026 17:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara (CERT) Taps NVIDIA For AI Drug Development, Is It A Bargain?", "summary": "Certara (CERT) announced a partnership with NVIDIA to integrate the BioNeMo Agent Toolkit into its open AI platform for drug development, driving recent investor interest and a 30-day share price increase of over 30%. While some valuation models suggest Certara is undervalued due", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-cert/certara/news/certara-cert-taps-nvidia-for-ai-drug-development-is-it-a-bar/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-14T10:42:15", "published_display": "14 Jul 2026 10:42", "sentiment": "positive", "sentiment_pct": 62, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Certara (CERT)'s NVIDIA BioNeMo Partnership Means For Shareholders", "summary": "Certara announced a partnership with NVIDIA to integrate the BioNeMo Agent Toolkit into its AI-driven biosimulation platform. This collaboration aims to enhance drug development tasks and reshape computational biology workflows, aligning with Certara's strategy to make AI-enabled", "url": "https://www.sahmcapital.com/news/content/what-certara-certs-nvidia-bionemo-partnership-means-for-shareholders-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-10T01:10:58", "published_display": "10 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara faces securities fraud probe after Q1 r...", "summary": "Certara, Inc. is under investigation by Pomerantz LLP for potential securities fraud. This probe follows a Q1 2026 report revealing a 4% decline in services revenue, a 14% drop in bookings, and the company's decision to exit its regulatory business segment due to inconsistent per", "url": "https://pluang.com/en/news-feed/peringatan-investor-pomerantz-selidiki-tuntutan-pemegang-saham-certara", "source_name": "Pluang", "published_at": "2026-07-09T21:45:06", "published_display": "09 Jul 2026 21:45", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT", "summary": "Pomerantz LLP is investigating potential claims on behalf of investors of Certara, Inc. (NASDAQ: CERT) regarding possible securities fraud or unlawful business practices. This investigation follows Certara's reported decline in services revenue and bookings in Q1 2026, its exit f", "url": "https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-certara-inc---cert-302822346.html", "source_name": "PR Newswire", "published_at": "2026-07-09T17:39:00", "published_display": "09 Jul 2026 17:39", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BlackRock (CERT) discloses 18.0M shares; 11.6% ownership reported", "summary": "BlackRock, Inc. has filed an amended Schedule 13G disclosing beneficial ownership of 18,032,062 shares of Certara, Inc. common stock, which represents an 11.6% stake in the company. The filing specifies that BlackRock holds sole voting power over 17,841,248 shares and sole dispos", "url": "https://www.stocktitan.net/sec-filings/CERT/schedule-13g-a-certara-inc-amended-passive-investment-disclosure-1c05b13791df.html", "source_name": "Stock Titan", "published_at": "2026-07-09T01:10:56", "published_display": "09 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AI Chips Today - Certara-NVIDIA Partnership Revolutionizes AI in Drug Development", "summary": "Certara has partnered with NVIDIA to integrate the NVIDIA BioNeMo Agent Toolkit into its AI platform for drug discovery and development. This collaboration aims to accelerate drug development by using AI-driven agents and biosimulation models to computationally simulate human bio", "url": "https://simplywall.st/stocks/us/semiconductors/nasdaq-nvda/nvidia/news/ai-chips-today-certara-nvidia-partnership-revolutionizes-ai", "source_name": "Simply Wall Street", "published_at": "2026-07-08T11:10:17", "published_display": "08 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara partners with Nvidia to integrate AI agents into drug development platform", "summary": "Certara, Inc. announced a partnership with Nvidia to integrate AI-driven agent technology, specifically Nvidia\u2019s BioNeMo Agent Toolkit, into its drug development platform. This collaboration aims to enhance drug development processes by generating insights across various stages, ", "url": "https://www.investing.com/news/company-news/certara-partners-with-nvidia-to-integrate-ai-agents-into-drug-development-platform-93CH-4779100", "source_name": "Investing.com", "published_at": "2026-07-08T01:10:56", "published_display": "08 Jul 2026 01:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nvidia Powers AI Agent Strategies for Certara, Silo Pharma - NVIDIA (NASDAQ:NVDA)", "summary": "Nvidia is expanding its influence in the life sciences AI sector through collaborations with Certara Inc. and Silo Pharma Inc. Certara is integrating Nvidia's BioNeMo Agent Toolkit into its AI-driven drug development platform to enhance drug discovery workflows, while Silo Pharma", "url": "https://www.benzinga.com/news/health-care/26/07/60316675/certara-silo-pharma-advance-ai-agent-strategies-with-nvidia-initiatives", "source_name": "Benzinga", "published_at": "2026-07-07T18:41:02", "published_display": "07 Jul 2026 18:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara teams up with Nvidia to strengthen AI platform with BioNeMo toolkit (CERT)", "summary": "", "url": "https://finance.yahoo.com/m/1806ddc8-7492-3334-96ab-5de0bc407511/certara-teams-up-with-nvidia.html", "source_name": "InvestorsHub", "published_at": "2026-07-07T12:54:23+00:00", "published_display": "07 Jul 2026 12:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent Toolkit", "summary": "Certara is partnering with NVIDIA to enhance its integrated AI platform for drug discovery and development using the NVIDIA BioNeMo Agent Toolkit. This collaboration aims to unify Certara's biosimulation software, proprietary datasets, and scientific expertise with AI-driven agen", "url": "https://www.manilatimes.net/2026/07/07/tmt-newswire/globenewswire/certara-accelerates-drug-discovery-and-development-with-nvidia-bionemo-agent-toolkit/2379819", "source_name": "The Manila Times", "published_at": "2026-07-07T12:05:20", "published_display": "07 Jul 2026 12:05", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara teams with NVIDIA to speed drug discovery with AI agents", "summary": "Certara announced a partnership with NVIDIA to integrate the NVIDIA BioNeMo Agent Toolkit into its open integrated AI platform. This collaboration aims to accelerate drug discovery and development by enabling AI agents to autonomously generate specialized insights across the life", "url": "https://www.stocktitan.net/news/CERT/certara-accelerates-drug-discovery-and-development-with-nvidia-bio-xvymzo9l011a.html", "source_name": "Stock Titan", "published_at": "2026-07-07T12:00:20", "published_display": "07 Jul 2026 12:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Certara, Inc. \u2013 HAM:700", "summary": "This article provides the \"Price to earnings forward\" value for Certara, Inc. (HAM:700) on the Hamburg Stock Exchange. It includes details about the period, value, and change, noting that the data is provided by FactSet Research Systems Inc.", "url": "https://www.tradingview.com/symbols/HAM-700/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T16:39:18", "published_display": "06 Jul 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Certara, Inc. \u2013 HAM:700", "summary": "This article provides financial information for Certara, Inc. (HAM:700), specifically focusing on its Price to Sales forward metric. The content highlights the company's stock exchange listing on the Hamburg Stock Exchange and indicates that no recent trades have occurred.", "url": "https://www.tradingview.com/symbols/HAM-700/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T12:13:30", "published_display": "05 Jul 2026 12:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Certara, Inc. \u2013 NASDAQ:CERT", "summary": "This article provides financial information for Certara, Inc. (NASDAQ: CERT), focusing on its enterprise value to revenue forward. The content appears to be a stub or a section of a larger financial data report, likely from TradingView, given the source and formatting. It details", "url": "https://www.tradingview.com/symbols/NASDAQ-CERT/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T02:10:39", "published_display": "05 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Certara, Inc. \u2013 HAM:700", "summary": "This article provides a brief mention of Certara, Inc.'s enterprise value to revenue forward, listed on the Hamburg Stock Exchange under the ticker HAM:700. It appears to be a stub or a section within a larger financial data platform, indicating the company's financial overview i", "url": "https://www.tradingview.com/symbols/HAM-700/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T01:40:28", "published_display": "05 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara (CERT) Could Be 33% Below Fair Value Following Russell Index Shift", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Certara (CERT) Quietly Recasting Its Small-Cap Identity Around Biosimulation Advisory Leadership?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/certara-cert-quietly-recasting-small-170847792.html", "source_name": "Simply Wall St.", "published_at": "2026-07-02T17:08:47+00:00", "published_display": "02 Jul 2026 17:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Certara (CERT) Joining the Russell 2000 Recast Its Biosimulation Investment Narrative?", "summary": "Certara, Inc. (CERT) has been reclassified into the Russell 2000 index, indicating a shift towards smaller-cap status, while also launching its Bio Venture Catalyst for early-stage biotechs and announcing a CFO transition. This article examines how the index change, coupled with ", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-cert/certara/news/does-certara-cert-joining-the-russell-2000-recast-its-biosim", "source_name": "Simply Wall Street", "published_at": "2026-07-01T18:10:33", "published_display": "01 Jul 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should You Investigate Certara, Inc. (NASDAQ:CERT) At US$6.36?", "summary": "This article evaluates whether Certara, Inc. (NASDAQ:CERT) is a worthwhile investment at its current price of US$6.36. It likely delves into the company's financials, market position, and future prospects to help potential investors make an informed decision.", "url": "https://news.futunn.com/en/post/75335485/should-you-investigate-certara-inc-nasdaq-cert-at-us-6", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-06-30T23:39:58", "published_display": "30 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara, Inc.(NasdaqGS: CERT) added to Russell 2000 Index", "summary": "Certara, Inc. (NasdaqGS: CERT), a provider of biosimulation software and services, has been added to the Russell 2000 Index. This inclusion means the company's stock will now be part of this widely recognized small-cap index, potentially increasing its visibility and liquidity. T", "url": "https://www.marketscreener.com/news/certara-inc-nasdaqgs-cert-added-to-russell-2000-index-ce7f5fdfda8ff724", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T18:40:11", "published_display": "29 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Certara, Inc. \u2013 NASDAQ:CERT", "summary": "This article displays the \"Enterprise value to EBITDA forward\" for Certara, Inc. (NASDAQ: CERT) on TradingView. It provides financial data for the company within the Technology Services sector. The page highlights market information, with various disclaimers regarding data provid", "url": "https://www.tradingview.com/symbols/NASDAQ-CERT/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T00:11:22", "published_display": "29 Jun 2026 00:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara, Inc. (CERT) Investigation: Bronstein, Gewirtz & Grossman", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Certara, Inc. (NASDAQ:CERT) following a significant drop in its stock price. This comes after Certara reported a decline in services revenue and bookings for Q1 2026, alongside an exit from its regulatory busin", "url": "https://natlawreview.com/press-releases/certara-inc-cert-investigation-bronstein-gewirtz-grossman-llc-encourages-0", "source_name": "The National Law Review", "published_at": "2026-06-28T14:09:55", "published_display": "28 Jun 2026 14:09", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Certara, Inc. \u2013 NASDAQ:CERT", "summary": "This article provides financial data for Certara, Inc. (NASDAQ: CERT), specifically focusing on its enterprise value to EBIT forward metric. It also lists general information about the company on TradingView, including market data, news, and community features.", "url": "https://www.tradingview.com/symbols/NASDAQ-CERT/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T12:10:05", "published_display": "28 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Certara, Inc. \u2013 NASDAQ:CERT", "summary": "The article displays the \"Price to book forward\" metric for Certara, Inc. (NASDAQ: CERT). It appears to be a financial data point provided by TradingView, with data sourced from ICE Data Services and FactSet Research Systems Inc.", "url": "https://www.tradingview.com/symbols/NASDAQ-CERT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T06:41:43", "published_display": "28 Jun 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara, Inc. Actuals & Estimates (NASDAQ:CERT)", "summary": "This article provides an overview of Certara, Inc. (NASDAQ:CERT) stock, including current price, historical performance, analyst forecasts, and financial data. It details information such as market capitalization, earnings reports, revenue, net income, and volatility, while also ", "url": "https://www.tradingview.com/symbols/NASDAQ-CERT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T14:41:24", "published_display": "25 Jun 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CERT Stock Slides As Certara Faces Probes And CFO Exit", "summary": "", "url": "https://news.google.com/rss/articles/CBMidEFVX3lxTFAydkZRNkVqQktqZkRaR2tIYlJMbFpXSjF1UjJRamgteU5Ya0JYYV9ESlFqUldfbGgzZXltXzRBRlJDNEJuMkJYQktmZmtJSk84U3QtbU5UVXFhY29Ma21jWHNaU2N3dGZ6Nm9aNVlLX3QyeTU5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-06-21T07:00:00+00:00", "published_display": "21 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara (CERT) Stock Sees Fair Value Edges Lower As Analysts Trim Targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPYlVnYURjd3J5VEMxME1zRjdVZ1FwZlh4T0dDU0xKZ3B0UjNfYmVuSjBaUjFjZWRjZ2RKbFJGOFMxTElHWjFLWXpYa2t6dHFxVi1tc1hpSGM3M3lSSjZVTTVIT3A4eGZPc0NwSjNXYkF3QlU5Xzc0V2d4TGFmdVI1NzhSLTJ4ZzFLY290b01BSldqZHc2aWZVag?oc=5", "source_name": "Market source", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CFO transition at Certara (NASDAQ: CERT) as company reaffirms 2026 guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOTlBPeFkxR1hEakxZOVhJX2FTckxsblVlMnIwczZkalFxbEY4RzB3aFJTYUttRUduTnYydkgyWmxWMmczNi1iMlEtb3lmc2JIWlh0V29rOWVsczQwQS1vcXVSa0lMeGhXbThPYWt3akFyUlRFai1KNldRb2ZqX1JxZ3pWNUUyVFItNm5RN3YweUZ6SG9qQmxDVnlWYUwxY0FMbHc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Consider Buying Certara, Inc. (NASDAQ:CERT)?", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNakxiSTFqSWZjTVk5ci1tQ1RyeXVvSkZvZVlIUmFuWjljSDBQRmlSaWpaTWFHM1hEbWVlZU44OThfYnpkamhoeEtFOUdNc0RjNC16RGxtQmJHbnhOVmdtNG5WQmZib0QxdnJXSkxLeFVTQ19JdTlMNnhtMmtLZUs5eS1EX3RjRXNWRmVTRjluaUJPMlpNbVhlc09WNGNEMW1ZU0M3SnBEdERib3pxeUxCcV9wNXRoR2tBMndZUjVQZ9IBxAFBVV95cUxOdTJVNzNOQlYwX3lOMVpWS0FQYUVGNVpMV0VydVNYb29meFFUdkZ5ZXpUeDloNVc0S3g2bVJwMEd3VFVsMDcxZFBrWGxHbXlQNjNrV0U2R2VObVNjMDVrdGpvQUZEX2FkZ1JVMXlZbXF3dHdnYUhSUWhJUThxb3hieGZHME5kZnFqenpUOEpFeHJNS2NRNVR2T0RzSmdxU3o1d2hWVGJnN3Z6Mjk4NE9PVXlYRkQyWVdrZW5YTWtBTXlPdmdm?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Certara (CERT) Investors Can Read The Quiet Shift In The Valuation Story", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNdjkxNXgyQ2pueHZYOGwxYW1EaFNVbEF0U3Z5OHZfb2JpbldGbzdqN0JnS2hXMkQ2RkxPbk5Mb0FFYmJpTC0yUWxoOEpwbjhOVUFReEtEY21wbkVYSE56NmtneVZZaWNCb3ozVWZXaVVqWjlzb2RIc3B1YW1USXRoNkc3YmVtQzFXUV9XZXJMYlRObWM3NGQxbmZWenpNMkE?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Now An Opportune Moment To Examine Certara, Inc. (NASDAQ:CERT)?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOTk12cUdDNUFHT19jUGRweXN5a3pCU0VPODRoZHEyVERfU2VqX2c2RTY0blZMVGpEU2ZPdUtQQzBrTmlDb0lyQUVzYVBBUHpUb3lGSDBCTGQ0TjMyTEdMZkNiY3l0VS10czIwR3pfcVRnZnlMUU1nNzdzaUhRb3c3Ul9rcXFQenl6XzlNbFRRbjFfbjJaX2FnODNmTzZ6a0dINkVR?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara Q1 2026 Earnings: EPS Misses Estimates but Stock Gains 1.35% - Final Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOS25yWUlfN0llM1FDMTRDUl9uR2hKZDFFY2VXX0pfZVNRaXYwMTBuTExtSVl5TnhaTmpFWU9mRGxtUTBqeXRhNlRfa1haQlpJZGo3TXVOMmZWWnItX3RfV2lVQU04bDAybDU2REJKSzJLU29fTVpyTUhMTDMtcEs0T1JydVdTWjRhZkR6YXBKZ2hRVTRHalp1Wjdra2NyOERKaTVtcncyQWc5V0U?oc=5", "source_name": "lwvtexas.org", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 31, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intel, Micron gain premarket; Certara slips", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOS05EelRuNjRVaFpPTkpEcjJhbVMyQmlfWEd1dmx5N0FYQlN6azJuOGxDVng3ZlF5bEFSOHdRNWhFZVU0YUlleUNoQWVQQU1BNEFDS1UwT19FdzRBWlNIcWVNZkxydG5FcEx5V3VHeFJLSzN3ckpGci1MQUhqM0dpbExQYTdMUjRuaTBUcGtfN2lQSnFqREREdWZTOVk5bkE?oc=5", "source_name": "Investing.com", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara (NASDAQ:CERT) Q1 2026: Software Shines, but Divestiture and Mixed Metrics Weigh on Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxQNk1KWjA2RU9yN0hMZDdnampSTzNCRkIxTHZCX1ZZYjdCdDJ6VGg4T0s0TnNLWWFQaHdhVFljU1NRdTluay1VVDA1ZEg5YkdXQUw2Y1ZHM2wtX2laeElCejRBdURuSkJkQVNDRGc2NXN2aktiNXlOV0VfZC1zUEZYQkVMdzUzSlRVQU1ISTlJeVlVVEJRVU5HSkl2WkNUcEprZHNZQkVkRURMT2lMc3NDQXJZYUVSbkRuekh5M2FvOTZYWmZNT29xLVI1ZHN2RWJPNlNwTUVKbHJOLWtN?oc=5", "source_name": "ChartMill", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara (CERT) Shares Slide After Weak Full-Year Guidance Overshadows Revenue Beat", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOZ1R4Zm5PUHFodG9oaVpBXzlWcjRneGpNV0VtZHFpZDRPSnd4clY5YjBtNVB0VDVBSUVBQ1VHRnJkNmZNYXN2bnMxWGhOSzVGREVMQUlzNHBvSTR4YW1DUURNck5qTmFteVlmMWItRC10Szk3azhOb1FTX2g1bUZ0VFM5SV92QWFQTlZId2hyMmZsdXQ5MDA4OEctY0MtNTN4?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara, Inc. (CERT) Q1 Earnings Miss Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOeEx0dEpKMXVseXN3eXVZNXFpTDVoeDJRa3p4eW1HLWNaMHJGWkxJTHJOaGJ4eE43UWlHY0hhZk5vTmdPZzFmNFZ2TWdvaGZrcVRfVXNXNUk0aXh2TTNZem13eWZHS2FDdWp2RmVnVkNENDJoSXFCYjJmbG9OWHhsWEVEOFY2dFpiWE5wamIxbDAxVW80S2J4Nw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara Insider Ups Holding During Year", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQcnNWWUZQQVVYWU1oTG9ZRTFvSDN1STgyTHpuM2t0c3JiOEE3VXgxWjE0Q01NRWJMYVhkVjVYR08taC1UYWZNaGdSRmphYlJzeXdMeW14UWxkcUp2M3hwYk5zZkk1bUYxaVpBeHZEeE1aVkVmQ0I4aUk1T2JXMjlnalBIV3N2dUNBX1BQXzhwT05PLWVPZEhWekZldE5sYUl4YlI1TG5KVkRfNlHSAbABQVVfeXFMT0hpV25pR1NTZnRibEpOU3FWTzVpVEpUaVVmM3Nxb3UzOElDZExpZkxhbzVKdlhkLXU2eXVyVEhRcTdUSDdjcTZ2U3NreVI0SWNPU0dqQW9RREViR2NZZkg4X0hucHhnSENLUFotQ1B3RGlmcG1kaGxxZGN1SUt0T0g5ZGllbkFqQzB2YkFRcmZweXVUMG5ESTlYMTN0V1BGSWw0MmJrNWpNSVZKem8tVTk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Certara (CERT) Story Is Shifting As Analysts Recut Targets And Expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxObmdtWDBoYnhEaUlSN2JwSjZDRGlEbHhuelBaME5TZ0picHZIWnp6R21JMFRFTEtmX0FSNUtENUg4Y0poN2JuN2N0c0QxbkFJajVqNmNJN2hOdU1iZFVkdXdGRDFzSHdpc3g1alVsckE4a0VLdU0tMlEyVVA0U3NiR2tNcnZLMkxhbFc3a0s1OUNxRmc4UEd5UnNRZ253dnZCZ1Y4?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veristat to Acquire Certara's Regulatory and Medical Writing Business in Expansion of CRO Capabilities", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOc3lSU2JJY1E5M2NSZFJNcXNHWV9NWWVQZmxONTFocVg4b0ZyMlNWUVpIakJvQms2U1FVVWpNV3ZfUm1IcEFodkVnc2lXdmQtdEhaVXJUY2tKRWdCcU9FS052UmRXczI1dUlBNXN1QXluSm55a05vU1FCNVpyaGJRakQ4SnRHTmhEMXhVMkQyVDFHR3FYUUVHSTVxejNEWm91Y1hjUXJxYXc1MW05WlV6aFZCTDZqMW1xeHFCQVVEMlBkQzU2YWd3S3F1U25xT0M5WXc?oc=5", "source_name": "Applied Clinical Trials Online", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Certara (CERT) Story Is Evolving As Price Targets Reset And Growth Plans Lag", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQbHNPdGpBVnlDNVhWbVotbzRyT0Z4UkVNSHNqZE16dmpwd3BYdWpJa1lvdmxkbDlvaEtwU2h6aFNtZlhqQ09UQ2lXR094MDVkeVNtQld3dTdLUlJxVVREd01uQ3oyYUp3bldwOWdzcUwxeFNJWHZ6cHNhRnV2ZVJlcHBJLUUxWDF3dXJHRTEyZXZFWEEtZl91X1FKVHpSNWs?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara, Inc.'s (NASDAQ:CERT) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara, Inc. Appoints Jon Resnick as CEO, Succeeding William Feehery, Effective January 1, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNWl9ORjliejE3VUdsRnVjOEVxSkg1UFllZWtSTXcyQWF1eGRJVWhsdkZMal82eWx4aElrUUhFb0Vwc0thNnBwN0VtaV91U2pDWmdCTnpDdTBJUVpiRGxzUkJfTlphdHRJQ3lsbDBGN3FDbUxvWXVfaVRzb1VVSEYtWkR4N2VILTQ0MFhiRVJCWUFWR3pzXzRCdDJ6X1F5QUJjZ29XV05zZXB0MXM5MzIzYldib1l4amw3b2F1N1hWMF9iYlpqZExXRjhiRWRSa1h5MDRR?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-12-11T08:00:00+00:00", "published_display": "11 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CERT SEC Filings - Certara, Inc. 10-K, 10-Q, 8-K Forms", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE5BaHdBSlBLZXNNRjFZajdZY1JXZW5TWmh6N19LeVk4UFlNUjM4Q25MazM5bTJKNXJmQTk0NWtaQ0kzcUZsWERKczJPRjljVlV2NVVzbE4xSQ?oc=5", "source_name": "Stock Titan", "published_at": "2025-08-06T21:14:43+00:00", "published_display": "06 Aug 2025 21:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certara (CERT) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5ReGdKWGNUc3h4LVJsZHhsZlJrN3lIRmxqOGVrUV9EZjVIWkUzc3VqbnIzTHBIcWNBbm93WXluRm0tcHp2TnpJWW5ueEViUzZrRVY4?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:56:10+00:00", "published_display": "25 Apr 2025 00:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 97, "total_relevant": 49, "sentiment_summary": {"positive": 10, "negative": 7, "neutral": 32, "score": 50, "total": 49, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 14.3, "count": 26}, {"event": "earnings", "label": "Earnings", "weight": 5.5, "count": 10}, {"event": "deals", "label": "Deals and strategy", "weight": 3.85, "count": 7}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.2, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 10, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 6.77, "latest_week": "2026-07-10", "one_week_move": -2.9, "four_week_move": 30.2, "twelve_week_move": 8.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.123453, "market_dynamics_buy_signal": false, "relative_strength": -32.209749, "fair_value_gap": -44.3, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 46.1026, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.9% over one week, +30.2% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 58, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 8}, {"label": "Stock Titan", "count": 7}, {"label": "Market source", "count": 7}, {"label": "simplywall.st", "count": 4}, {"label": "Simply Wall Street", "count": 3}, {"label": "The Manila Times", "count": 2}, {"label": "Investing.com", "count": 2}, {"label": "scanx.trade", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 26}, {"label": "Earnings", "count": 10}, {"label": "Deals and strategy", "count": 7}, {"label": "Regulatory and legal", "count": 4}, {"label": "Balance sheet", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-2.9% over one week, +30.2% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026"}], "updated_at": "2026-07-16T11:42:42.870643+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}